Related Experiment Video
Updated: Jul 9, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis
David N Taylor1, Robin McKenzie, Anna Durbin
1Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. david.taylor@vaxinnate.com
Abstract:
Rifaximin is an oral antibiotic indicated for treatment of traveler's diarrhea. Rifaximin pharmacokinetics were evaluated in individuals challenged with Shigella flexneri. Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Pharmacokinetics in Pediatric Patients: Drug Excretion
Dosage Regimens: Partial Pharmacokinetic Parameters
Modified-Release Drug Delivery Systems: Bioavailability
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
